An Open Label, Phase 1 Study of SC-004 as Monotherapy and in Combination With ABBV-181 in Subjects With Epithelial Ovarian, Including Fallopian Tube and Primary Peritoneal and Endometrial Cancers

This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part B (dose expansion), potential therapeutic doses may be studied with SC-004 as monotherapy and SC-004 in combination with ABBV-181 in disease-specific cohorts.

Start Date14 Jun 2017

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with SC-004(Stemcentrx)

100 Translational Medicine associated with SC-004(Stemcentrx)

100 Patents (Medical) associated with SC-004(Stemcentrx)

Literatures (Medical) associated with SC-004(Stemcentrx)

01 Jun 2023·Case Studies in Chemical and Environmental Engineering

Life cycle assessment of Tehran Municipal solid waste during the COVID-19 pandemic and environmental impacts prediction using machine learning

Author: Hadadian, Mobina ; Shekoohiyan, Sakine ; Heidari, Mohsen ; Hosseinzadeh-Bandbafha, Homa

Life cycle assessment and machine learning were combined to find the best option for Tehran's waste management for future pandemics. The ReCipe results showed the waste's destructive effects after COVID-19 were greater than before due to waste composition changes. Plastic waste has changed from 7.5 to 11%. Environmental burdens of scenarios were Sc-1 (increase composting to 50%) > Sc-3 > Sc-4 > Sc-b2 > Sc-5 > Sc-2 (increase recycling from 9 to 20%). The artificial neural network and gradient-boosted regression tree could predict environmental impacts with high R². Based on the results, the environmental burdens of solid waste after COVID-19 should be investigated.

08 Mar 2023·Plants (Basel, Switzerland)

The Influence of Bacteria-Inoculated Mineral Fertilizer on the Productivity and Profitability of Spring Barley Cultivation.

Article

Author: Steponavicius, Dainius ; Zaleckas, Ernestas ; Sendzikiene, Egle ; Lekaviciene, Kristina ; Anusauskas, Justinas ; Romaneckas, Kestutis

The heavy use of mineral fertilizers causes imbalances in the biological processes that take place in soil. Therefore, it is necessary to develop more effective fertilizers or fertilizer complexes that ensure agricultural productivity and soil conservation. There is currently a lack of knowledge regarding the effectiveness of biologically enriched, complex mineral fertilizers for spring barley fertilization. The hypothesis of this study was that bacteria-enriched (Paenibacillus azotofixans, Bacillus megaterium, Bacillus mucilaginosus, and Bacillus mycoides), complex mineral fertilizers (N₅P_20.5K₃₆) have significant impacts on the yield and potential for economic use of spring barley. Experimental studies were carried out for three years (2020-2022) with sandy loam soil in southern Lithuania. Four different spring barley fertilization scenarios (SCs) were investigated. In SC-1 (control), complex mineral fertilizer (N₅P_20.5K₃₆) was not applied. In the other SCs, spring barley was sown with a drill and fertilizers were incorporated locally during the sowing operation: fertilization scenario SC-2 used 300 kg ha^-1, SC-3 used 150 kg ha^-1 preceded by a bacteria-inoculated complex mineral fertilizer (N₅P_20.5K₃₆), and SC-4 used 300 kg ha^-1 with the same bacterial complex. The results showed that the bacterial inoculant increased the efficiency of the mineral fertilizer and had an effect on plant growth in barley. For three consecutive years in the same plots, the bacterial inoculant showed significant positive effects on grain yield (changes of 8.1% in 2020, 6.8% in 2021, and 17.3% in 2022 between SC-2 and SC-4). Comparing the several different fertilizer scenarios from an economic point of view, it was observed that the highest profit per hectare was obtained with SC-4 in all three years of the study. Comparing SC-4 and SC-2, an increase of 13.7% was observed in 2020, followed by 9.1% and 41.9% in 2021 and in 2022, respectively. This study will be useful for farmers, biological inoculant manufacturers, and scientists researching the effectiveness of biological inoculants for growing agricultural crops. We found that it is possible to increase the yield of barley (7-17%) using the same rate of mineral fertilization by enriching it with bacterial inoculants. Further studies should be conducted to determine the effects of the bacterial inoculant on crop yield and soil over a period longer than 3 years.

30 Sep 2020·ACS Applied Materials & InterfacesQ2 · MATERIALS SCIENCE

Elucidating a Thermoresponsive Multimodal Photo-Chemotherapeutic Nanodelivery Vehicle to Overcome the Barriers of Doxorubicin Therapy

Q2 · MATERIALS SCIENCE

Article

Author: Maiti, Kaustabh Kumar ; Sreedevi, Padincharapad ; Sujai, Palasseri T. ; Arya, Jayadev S. ; Nair, Jyothi B. ; Joseph, Manu M.

In an attempt to circumvent the major pitfalls associated with conventional chemotherapy including drug resistance and off-target toxicity, we have adopted a strategy to simultaneously target both mitochondrial DNA (Mt-DNA) and nuclear DNA (n-DNA) with the aid of a targeted theranostic nanodelivery vehicle (TTNDV). Herein, folic acid-anchored p-sulfo-calix[4]arene (SC₄)-capped hollow gold nanoparticles (HGNPs) were meticulously loaded with antineoplastic doxorubicin (Dox) and its mitochondrion-targeted analogue, Mt-Dox, in a pretuned ratio (1:100) for sustained thermoresponsive release of cargo. This therapeutic strategy was enabled to eradicate both n-DNA and Mt-DNA leaving no space to develop drug resistance. The SC₄-capped HGNPs (HGNPSC₄) were experimented for the first time as a photothermal (PTT) agent with 61.6% photothermal conversion efficiency, and they generated tunable localized heat more efficiently than bare HGNPs. Moreover, the cavity of SC₄ facilitated the formation of an inclusion complex with folic acid to target the folate receptor expressing cancer cells and imparted enhanced biocompatibility. The as-synthesized TTNDV was demonstrated to be an ideal substrate for surface-enhanced Raman scattering (SERS) to monitor the molecular-level therapeutic progression in cells and a spheroidal model. A significant reduction in the tumor mass with a marked survival benefit was achieved in syngraft murine models through this synergistic photo-chemotherapy. Collectively, this multifunctional nanoplatform offers a robust approach to treat cancer without any scope of generating Dox resistance and off-target toxicity.

100 Deals associated with SC-004(Stemcentrx)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endometrial Carcinoma	Phase 1	US	AbbVie, Inc.	14 Jun 2017
Fallopian Tube Carcinoma	Phase 1	US	AbbVie, Inc.	14 Jun 2017
Ovarian Epithelial Carcinoma	Phase 1	US	AbbVie, Inc.	14 Jun 2017
Peritoneal Neoplasms	Phase 1	US	AbbVie, Inc.	14 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SC-004(Stemcentrx)

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation